<DOC>
	<DOCNO>NCT01032954</DOCNO>
	<brief_summary>This open-label phase IV study full face injection variable dos BT-A . As open-label blind study , investigator subject know injection local dos study drug . Patients randomize 3 different group . Each group receive specific dose accord indication evaluate investigator . Six visit schedule study .</brief_summary>
	<brief_title>Safety Efficacy Full Face Applications Variable Doses Commercial Botulinum Toxin Type ( Dysport® )</brief_title>
	<detailed_description>4.2 Methodology 4.2.1 Patient evaluation After provide write informed consent , subject 's eligibility assess Screening Visit . The subject 's general medical history record . This include demographic data , history surgical cosmetic procedure , dermatological assessment , physical examination , prior concomitant medication . A pregnancy test also perform . 4.2.1.1 Severity wrinkle One sub-investigator rate wrinkle follow validated severity scale main area face relaxed mode maximal contraction , visit 0 , visit 2 ( week 4 ) 3 ( week 16 ) : - Clinical 0-3 score glabellar frown lines7 ( Annex 4 ) - Photonumeric Atlas Assessment Crow 's Feet Severity8 ( Annex 5 ) - Photonumerical Atlas Assessment Forehead Wrinkle Severity9 ( Annex 6 ) - Marionette Lines Grading Scale10 ( Annex 7 ) 4.2.1.2 Standard set photograph take At Screening , 2 , 3 , 4 5 visit , photograph take : All photograph take standardized photographic mode fix position camera . A guideline example standardize photo delimit standardized position provide person responsible take photo . In photograph , research subject identify tag contain reference study , number research subject control date . The research subject wash face photographic procedure remove excess oil make remove . All picture take room parameter . The photograph set consist - Full face frontal view relax ; - One set photograph relax contracted indication patient treat study . At end study , two independent evaluator ( dermatologist ) ass picture blind manner . This evaluation do assess efficacy BT-A inject area assess scale . 4.2.3 Evaluation Quality Life patient-reported complains , outcome satisfaction Patients invite answer WHOQoL bref ( Annex 2 ) . They also answer questionnaire regard believe , expectation spontaneous complaint treatment ( Annex 3 ) . This questionnaires answered patient visit : screening , 2 , 3 , 4 e 5. . 4.2.4 Groups treatment Subjects assign one three follow treatment group , accord total dose receive visit 1 : - Group 1 : 30 subject receive 125 170 U BT-A ( Dysport® ) - Group 2 : 30 subject receive 171 210 U BT-A ( Dysport® ) - Group 3 : 30 subject receive 211 250 U BT-A ( Dysport® ) 4.2.5 Reconstitution study product Treatment Administration An independent , experienced register pharmacist assign carry reconstitution product . She prepare dilution syrinx product ( DYSPORT® ) immediately prior injection . The dilution DYSPORT® 500 Units per vial make 2 mL 0.9 % sterile saline , use 3 mL syrinx 21G needle , give concentration 250 Units/mL 2.5Units/0.01mL reconstitute product . An experienced dermatologist use botulinum toxin ( principal investigator - DH ) perform injection accord indication total number unit inject accord treatment plan , aim obtain best result . She perform injection participate phase study . The application BT-A make BD Ultra-fine II 0.3cc syrinx , 29G needle , 0.5cm length ( short needle ) . Immediately application , side effect verify need , register manage .</detailed_description>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Written Informed Consent ; 2 . Subjects age 30 60 year ; 3 . Skin Fitzpatrick Phototypes I VI ; 4 . Subjects never receive BTA previous injection BTA one third face last 6 month ; 5 . Subjects present least two indication treatment BTA third face ; 6 . Medical history physical examination , base investigator 's opinion , prevent patient take part study use product investigation ; 7 . Subjects childbearing age present negative urine pregnancy test ( instant test ) baseline use effective contraceptive method ( oral injectable contraceptive , last three month , use preservative ; subject : hysterectomy , oophorectomy tubal ligation ) ; 8 . Availability patient throughout duration study ( 24 week ) ; 9 . Subjects agree undergo cosmetic dermatological procedure study ; 10 . Subjects sufficient school awareness enable cooperate degree require study protocol . 1 . Pregnant woman woman intend become pregnant study ; 2 . Subjects participate clinical trial ; 3 . Presence scar face may interfere result study ; 4 . Subjects neoplastic , muscular neurological disease ; 5 . Concurrent use treatment affect neuromuscular transmission , curarelike depolarize agent , lincosamides , polymyxin , anticholinesterase affect striated muscle aminoglycoside antibiotic . 6 . Subjects inflammation active infection face ; 7 . Subjects history sensitivity component formula ; 8 . Subjects prior history eyelid ptosis ; mark facial asymmetry , excessive dermatochalasis , deep dermal scar thick sebaceous skin . 9 . Subjects present myasthenia gravis , EatonLambert Syndrome motor neuron diseases ; 10 . Subjects coagulation disorder use anticoagulant ; 11 . Subjects know systemic autoimmune disease ; 12 . Subjects clinically diagnose anxiety disorder significant psychiatric disorder ( e.g . depression ) , opinion Evaluator , might interfere Subject 's participation study ; 13 . Subjects history medical treatment nonadherence show unwillingness adhere study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Botulinum Toxin</keyword>
	<keyword>Rejuvenation</keyword>
	<keyword>Facial dynamic wrinkle</keyword>
</DOC>